The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
According to the estimates by IMARC Group, the global point-of-care diagnostics market is expected to witness a CAGR of 3.25% from 2021 to 2026.
The growing prevalence of chronic diseases that require timely diagnosis and rapid screening represents one of the key drivers for the global point-of-care diagnostics market.
The advent of home-testing cancer kits, which can actively monitor and analyze tumor cells, along with the growing number of R&D activities to develop molecular diagnostic devices, represent some of the key trends in the global point-of-care diagnostics market.
Sudden outbreak of the COVID-19 pandemic has led to an increasing demand for point-of-care diagnostics due to the surge in clinical experiments for the diagnosis of coronavirus disease.
On the basis of the product type, the market has been segmented into blood-glucose monitoring kit, cardio-metabolic monitoring kit, pregnancy and fertility testing kit, infectious disease testing kit, cholesterol test strip, hematology testing kit, and others. Among these, blood-glucose monitoring kit accounts for the majority of the market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global point-of-care diagnostics market are Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Instrumentation Laboratory, Johnson & Johnson, Nova Biomedical Corporation, Pts Diagnostics, Qiagen, Siemens, Trinity Biotech, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at